Oruka Therapeutics, Inc. Common StockORKA
About: Oruka Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing novel monoclonal antibody therapeutics for psoriasis (PsO) and other inflammatory and immunology (I&I) indications. Its lead program, ORKA-001, is designed to target the p19 subunit of interleukin-23 (IL-23p19) for the treatment of PsO. The company's co-lead program, ORKA-002, is designed to target interleukin-17A and interleukin-17F (IL-17A/F) for the treatment of PsO, psoriatic arthritis (PsA), and other conditions. These programs each bind their respective targets at high affinity and incorporate half-life extension technology to increase exposure and decreasing dosing frequency.
Employees: 28
Fund manager confidence
Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)
625% more first-time investments, than exits
New positions opened: 29 | Existing positions closed: 4
150% more repeat investments, than reductions
Existing positions increased: 20 | Existing positions reduced: 8
61% more funds holding
Funds holding: 41 [Q3] → 66 (+25) [Q4]
18.51% more ownership
Funds ownership: 70.17% [Q3] → 88.68% (+18.51%) [Q4]
0% more capital invested
Capital invested by funds: $604M [Q3] → $607M (+$2.45M) [Q4]
25% less funds holding in top 10
Funds holding in top 10: 4 [Q3] → 3 (-1) [Q4]
Research analyst outlook
2 Wall Street Analysts provided 1 year price targets over the past 3 months
2 analyst ratings
HC Wainwright & Co. Mitchell Kapoor 33% 1-year accuracy 60 / 182 met price target | 272%upside $45 | Buy Reiterated | 7 Feb 2025 |
Wolfe Research Andy Chen 40% 1-year accuracy 6 / 15 met price target | 65%upside $20 | Outperform Initiated | 4 Feb 2025 |
Financial journalist opinion








